“Australia has been recognized globally for its handling of the COVID-19 pandemic with strict quarantine systems and advanced contact tracing, resulting in low numbers of cases and deaths. Therefore we have seen a dramatic increase in the number of USA sponsors moving their trials to Australia.” Read the full article here
The global disruption presented a number of operational challenges including:
- A need to rapidly pivot to full adoption of eClinical technologies because traditional working practices and methods were no longer practical.
- Initially, patient/volunteer participation in clinical trials decreased at some sites because participants were not wanting to attend clinics or hospitals for fear of the virus.
- Some sites in Australia were temporarily closed while they introduced new work practices to protect staff and patients/volunteers.
- COVID-19 studies targeting countries with significant patient populations, rapidly dominated the global sector, resulting in decreased attention, site resources and funding for non-COVID related therapies.
- Employee adaptions to new working environments i.e. working from a home office.
- Conduct of business development activities needed to change as the ability to create new business connections and partnerships via conferences and face-to-face meetings became no longer possible.